UCB SA (EBR:UCB)
251.00
-6.90 (-2.68%)
At close: Mar 6, 2026
UCB SA Employees
UCB SA had 8,600 employees as of June 30, 2025. The number of employees decreased by 778 or -8.30% since the number was reported on December 31, 2024.
Employees
8,600
Change
-778
Growth
-8.30%
Revenue / Employee
€792,729
Profits / Employee
€159,549
Market Cap
47.78B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| argenx SE | 1,599 |
| Onward Medical | 103 |
| Hyloris Pharmaceuticals | 50 |
| European Medical Solutions | 123 |
| Celyad Oncology | 19 |
| BioSenic | 7 |
| Oxurion NV | 11 |
UCB SA News
- 3 days ago - Belgium's UCB in autoimmune drug deal with Antengene - Reuters
- 5 days ago - UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ... - GuruFocus
- 5 days ago - Full Year 2025 Ucb SA Earnings Call Transcript - GuruFocus
- 5 days ago - Best Income Stocks to Buy for March 2nd - Nasdaq
- 16 days ago - Decoding United Community Banks Inc (UCB): A Strategic SWOT Insight - GuruFocus
- 23 days ago - Best Income Stocks to Buy for February 12th - Nasdaq
- 4 months ago - U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) - PRNewsWire